Few biopharma risers stand out at the half year
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
Are we there yet?
Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.
Covid vaccine development could go Omicron-and-on
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
Roche deal fails to Repare the licensing scene
Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.
Go or no go? The FDA’s Amylyx dilemma
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
